Note 20. Parent entity information (Continued) Statement of financial position Parent 2025 2024 $ $ Total current assets 4,577,480 4,768,266 Total assets 9,537,544 9,908,660 Total current liabilities 3,870,211 1,246,394 Total liabilities 3,891,442 1,288,613 Equity Issued capital 74,635,721 74,635,721 Options reserve 700,064 929,767 Accumulated losses (69,689,683) (66,945,441) Total equity 5,646,102 8,620,047 Guarantees entered into by the parent entity in relation to the debts of its subsidiaries The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2025. Contingent liabilities Except as outlined in note 18, the parent entity had no contingent liabilities as at 30 June 2025 and 2024. Capital commitments - Property, plant and equipment The parent entity had no capital commitments at 30 June 2025 and 2024. Material accounting policy information The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 1. Note 21. Interests in subsidiaries and associates The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1: Ownership interest Principal place of business / Country of incorporation 2025 2024 Name % % Norbio Holding Pty Ltd Australia 100.00% 100.00% Noxopharm US Corporation USA 100.00% 100.00% Pharmorage Pty Limited Australia 100.00% 100.00% Annual Report 2025 41
RkJQdWJsaXNoZXIy MjE2NDg3